Incyte
INCY
Market cap $13.1B

67.75 USD

-1.47

2.12%

At close Jun 13, 4:00 PM EDT

After hours

67.75

+0.00

0.00%

1 day

-2.12%

5 days

-1.65%

1 month

11.41%

3 months

0.06%

6 months

-1.17%

Year to date

-2.56%

1 year

8.07%

5 years

-27.55%

10 years

-34.65%

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Employees: 2,617

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

57% more call options, than puts

Call options by funds: $47.5M | Put options by funds: $30.3M

16% more repeat investments, than reductions

Existing positions increased: 252 | Existing positions reduced: 217

2.09% more ownership

Funds ownership: 94.68% [Q4 2024] → 96.77% (+2.09%) [Q1 2025]

4% less funds holding

Funds holding: 637 [Q4 2024] → 613 (-24) [Q1 2025]

10% less capital invested

Capital invested by funds: $12.6B [Q4 2024] → $11.3B (-$1.26B) [Q1 2025]

11% less first-time investments, than exits

New positions opened: 73 | Existing positions closed: 82

50% less funds holding in top 10

Funds holding in top 10: 8 [Q4 2024] → 4 (-4) [Q1 2025]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$59

13%

downside

Avg. target

$69

2%

upside

High target

$92

36%

upside

7 analyst ratings

0 positive

0%

7 neutral

100%

0 negative

0%

UBS Ashwani Verma	10%downside $61	Neutral Maintained	3 Jun 2025
Truist Securities Srikripa Devarakonda	8%upside $73	Hold Maintained	27 May 2025
Wells Fargo Derek Archila	13%downside $59	Equal-Weight Maintained	30 Apr 2025
RBC Capital Brian Abrahams	1%downside $67	Sector Perform Maintained	30 Apr 2025
JP Morgan Jessica Fye	0%upside $68	Neutral Maintained	21 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about INCY published over the past 30 days

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofi.

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025.

Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

WILMINGTON, Del.--(BUSINESS WIRE)--Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet.

Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025.

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

20 stocks primed for rapid growth while trading at half of Nvidia's valuation

When selecting investments, it is easy to get hung up on a particular metric, such as a dividend yield or a price ratio, but investors need to look deeper or they might miss opportunities.

20 stocks primed for rapid growth while trading at half of Nvidia's valuation

Zacks Investment Research

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development.

Incyte to Present at Upcoming Investor Conference

Zacks Investment Research

Incyte Gets FDA Approval for Zynyz in New Cancer Indication

The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.

Incyte Gets FDA Approval for Zynyz in New Cancer Indication

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States.

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

See News Rankings

Charts implemented using Lightweight Charts™